ストックスクリーナーアプリを入手
14.46
4.55%
-0.69
アフターアワーズ：
14.46
Immunovant Inc (IMVT) 最新ニュース
Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus - insights.citeline.com
Immunovant Names New CEO, CFO - marketscreener.com
Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated - MSN
Roivant Sciences Announces Leadership Changes at Immunovant - TipRanks
Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications - TradingView
Immunovant Announces New CEO Amid Strategic Shift - TipRanks
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 - The Manila Times
Immunovant (IMVT) Announces Leadership Changes - StreetInsider
Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role - Stock Titan
Alliancebernstein L.P. Grows Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView
(IMVT) On The My Stocks Page - news.stocktradersdaily.com
Geode Capital Management LLC Boosts Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Thyroid Eye Disease Market Predicted to See Upsurge Through - openPR.com
Wellington Management Group LLP Lowers Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant CEO Peter Salzmann sells shares worth $364,941 By Investing.com - Investing.com South Africa
Raymond James Financial Inc. Takes Position in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Immunovant CEO Peter Salzmann sells shares worth $364,941 - Investing.com
Immunovant CEO Peter Salzmann Sells Shares to Cover Tax Obligations - TradingView
JPMorgan Chase & Co. Has $28.57 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant stock hits 52-week low at $13.58 amid market challenges - Investing.com Australia
Immunovant stock hits 52-week low at $13.58 amid market challenges By Investing.com - Investing.com South Africa
Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires? - Insider Monkey
Immunovant, Inc. (NASDAQ:IMVT) Shares Acquired by Sei Investments Co. - Defense World
Raymond James Financial Inc. Makes New $505,000 Investment in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Norges Bank Purchases Shares of 637,947 Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Did an AI Discriminate in Hiring? Employer Faces Lawsuit - Law.com
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Vanguard Group Inc. - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Stock Holdings Lowered by Corebridge Financial Inc. - Defense World
KLP Kapitalforvaltning AS Acquires Shares of 10,800 Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant is Now Oversold (IMVT) - Nasdaq
Teacher Retirement System of Texas Has $377,000 Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) PT at $41.00 - Defense World
How the (IMVT) price action is used to our Advantage - news.stocktradersdaily.com
Immunovant stock hits 52-week low at $17.01 amid market challenges - Investing.com
Swiss National Bank Grows Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Batoclimab eases disease severity; Immunovant backs IMVT-1402 - Myasthenia Gravis News
Guggenheim Reiterates Buy Rating for Immunovant (NASDAQ:IMVT) - MarketBeat
Teenager dies after receiving Sarepta therapy; Immunovant gets Phase 3 win, but shifts focus; Alnylam’s big moment; and more - Endpoints News
Charles Schwab Investment Management Inc. Increases Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Bank of America Has Lowered Expectations for Immunovant (NASDAQ:IMVT) Stock Price - Defense World
Immunovant price target raised to $61 from $58 at Stifel - Yahoo Finance
Long Term Trading Analysis for (IMVT) - news.stocktradersdaily.com
HC Wainwright Reiterates “Buy” Rating for Immunovant (NASDAQ:IMVT) - Defense World
Immunovant stock hits 52-week low at $17.15 amid market challenges - Investing.com Australia
Stifel raises Immunovant stock price target to $61 from $58 By Investing.com - Investing.com Canada
Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate - TradingView
Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright - Yahoo Finance
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success - TradingView
Immunovant stock holds $51 target on positive trial data By Investing.com - Investing.com Canada
Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Victory Capital Management Inc. - Defense World
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT) - Seeking Alpha
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data - AOL
Immunovant’s Batoclimab Shows Promising Efficacy in MG and CIDP, Justifying Buy Rating - TipRanks
Immunovant will not seek approval for MG therapy, despite hitting endpoints - Yahoo Finance
Immunovant's muscle drug meets main goal, shares gain on new drug promise - Reuters.com
Immunovant claims study success for immune disease drug but holds off on submission - BioPharma Dive
Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another - BioSpace
Immunovant stock hits 52-week low at $17.15 amid market challenges By Investing.com - Investing.com South Africa
Positive batoclimab data from Immunovant, but doubts raised on further development - The Pharma Letter
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):